How false drug test results put children at risk

Confirmatory gas chromatography-mass spectrometry drug testing in pediatric patients: a clinical case series highlighting false-positive results and child protection implications.

Journal of analytical toxicology β€’ β€’ Case Study β€’ Moderately Relevant
πŸ€–

AI Summary

This clinical case series examines false-positive and false-negative results in urine drug screening of young children (0-5 years) using confirmatory testing with gas chromatography-mass spectrometry (GC-MS). The study tracked 14 pediatric patients who initially tested positive on immunoassay urine drug screensβ€”a rapid but less accurate screening method. When these results were confirmed using the more reliable GC-MS technique at a reference laboratory, the findings revealed a critical problem: many initial positive results were inaccurate, caused by cross-reactivity of the immunoassay antibodies with unrelated compounds, or by substances that were completely missed during initial screening.

The research identified numerous substances confirmed through GC-MS, including cocaine metabolites, prescription medications like lorazepam and sertraline, and notably, cannabis metabolite 11-nor-Ξ”9-tetrahydrocannabinol-9-carboxylic acid (THCCOOH). The study demonstrates that confirmatory testing directly influenced clinical management decisions and supported child protection interventions in cases of suspected neglect, accidental poisoning, or environmental exposure. This finding has profound implications: relying solely on initial immunoassay screening without confirmation can lead to incorrect diagnoses, inappropriate medical treatments, and potentially wrongful child protection actions based on false-positive results.

The research underscores the critical importance of using definitive analytical methods like GC-MS before making clinical decisions or legal determinations in pediatric toxicology cases. For cannabis specifically, this study highlights how THC metabolites can be accurately identified and distinguished from interfering substances only through confirmatory testing, ensuring that positive results truly represent actual exposure rather than false alarms. The findings advocate for stronger protocols that require confirmation testing before any clinical action or child protective services involvement.

πŸ“„ Original Abstract

Drug exposure in pediatric patients represents a major clinical and forensic challenge, particularly when initial urine drug screening relies on immunoassays with limited specificity. False-positive and false-negative results may lead to inappropriate clinical decisions or delayed child protection interventions. We conducted a retrospective case series of 14 pediatric patients (0-5 years) with suspected drug exposure evaluated in a hospital emergency setting. Positive immunoassay urine drug screens were submitted for confirmatory analysis using gas chromatography-mass spectrometry (GC-MS) at a reference toxicology laboratory. GC-MS confirmation identified a wide range of illicit and prescription substances and metabolites, including benzoylecgonine, cocaine, ecgonine methyl ester, phenobarbital, para-hydroxy-phenobarbital, lorazepam, morphine, sertraline and its metabolites, hydroxymidazolam, MDMA, MDA, and 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid (THCCOOH). In several cases, GC-MS resolved discordant screening results by identifying immunoassay false positives caused by cross-reactivity or by detecting substances missed during initial screening. Confirmatory GC-MS testing directly influenced clinical management and supported child protection decisions in cases of suspected neglect, accidental ingestion, or environmental exposure. These findings reinforce the critical role of mass spectrometry-based confirmation in pediatric toxicology to ensure diagnostic accuracy and appropriate clinical and legal outcomes.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.